Therapeutics News and Research

RSS

Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009

Tikcro Technologies Ltd. today reported results for the fourth quarter and year ended December 31, 2009.

17 Apr 2010

Akela to terminate lease payment agreement

Akela a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today announced that it has reached agreement with HEP Davis Spring, L.P. to terminate its lease located at 9825 Spectrum Drive, Austin, Texas, eliminating $14,500,000 in future lease payment obligations to the Company.

17 Apr 2010

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.

16 Apr 2010

New study may help devise better treatment strategies for cancer and heart disease

Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer.

16 Apr 2010

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Idera Pharmaceuticals, Inc. announced today that positive interim data from a Phase 1 clinical trial of IMO-2125, a Toll-like Receptor 9 (TLR9) agonist, in null responder patients with chronic hepatitis C virus (HCV) infection were presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).

16 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Sunlight Research – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape. Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.

16 Apr 2010

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

16 Apr 2010

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.

16 Apr 2010

Sorrento Therapeutics completes construction of fully human mAbs library

Sorrento Therapeutics, Inc. today announced that it has completed the construction of an extensive library of full-length, fully human monoclonal antibodies (mAbs). Initial analysis indicates a potential diversity of more than one trillion unique mAbs. The company believes this makes its library the largest full-length, fully human antibody library available for drug discovery and development partnerships.

15 Apr 2010

Repros Therapeutics announces compliance for continued listing on Nasdaq Capital Market

Repros Therapeutics Inc. today announced that it believes that it has regained compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

15 Apr 2010

Cell Therapeutics reduces workforce to cut operating costs

Cell Therapeutics, Inc. today announced it has conducted an immediate reduction in force of 36 employees. The Company expects the reduction in force and elimination of previously planned increase in commercial personnel along with a reduction in planned operating expenses to result in savings of approximately $16 million in 2010.

15 Apr 2010

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting

Achillion Pharmaceuticals, Inc. today presented data from the Company's ongoing Phase 1 clinical trial of ACH-1625 to treat hepatitis C at the European Association for the Study of the Liver's International Liver Congress taking place at the Reed Messe Wien Congress Center in Vienna, Austria from April 14-18, 2010.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

Opexa Therapeutics presents key efficacy data on Tovaxin

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company presented key efficacy data at the American Academy of Neurology 62nd Annual Meeting held in Toronto, Canada.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

Use of silver dressing in burn cases questioned

The use of expensive silver dressing in burn cases is being brought under the scanner by an editorial in the Drug and Therapeutics Bulletin. The NHS has increased its spending from £23 million in 2005 to around £25 million in 2006/7 on such products. The author asks if expensive silver dressing is really justified when cheaper alternatives are available.

15 Apr 2010

Therapeutics News and Research

Tikcro Technologies reports net loss of $1.8M for fourth-quarter 2009

Akela to terminate lease payment agreement

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

New study may help devise better treatment strategies for cancer and heart disease

Positive interim data from Idera Pharmaceuticals' Phase 1 trial of IMO-2125 TLR9 agonist presented at 45th EASL

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Sorrento Therapeutics completes construction of fully human mAbs library

Repros Therapeutics announces compliance for continued listing on Nasdaq Capital Market

Cell Therapeutics reduces workforce to cut operating costs

Phase 1 clinical trial results of Achillion Pharmaceuticals' ACH-1625 to be presented at EASL meeting

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Opexa Therapeutics presents key efficacy data on Tovaxin

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Phase IIa clinical trial results of Serdaxin for treatment of MDD

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

Use of silver dressing in burn cases questioned

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News